SEC Form 4 · accession 0001019056-16-001459
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zsolt Harsanyi
Director
Period of report
Aug 3, 2016
Accepted (ET)
Aug 5, 2016 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 7,383 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.94 | Aug 3, 2016 | A | 18,750 | A | — | Aug 3, 2026 | Common Stock | 18,750 | 18,750 | D |
Explanation of responses
- F1Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective on August 1, 2016.
- F2The stock options were granted on August 3, 2016 and vest in three equal installments on August 3, 2017, August 3, 2018 and August 3, 2019.